The Tbit™ blood test uses a patented nanotechnology biosensor to rapidly detect and accurately measure protein biomarkers that are released from the brain immediately following a head trauma. The portable technology platform allows for testing to be performed at the earliest stages of a concussion. Early objective diagnostic testing of patients who have experienced head trauma can support more rapid and appropriate treatment decisions while potentially reducing unnecessary head CT scans.
In pre-clinical human sample testing, the Tbit™ blood test has been shown to offer high levels of both sensitivity and accuracy in measurement of biomarkers associated with traumatic injury in blood.
"We believe that our review with the FDA effectively communicated that the Tbit™ is a unique technology with the clear potential to radically improve the way concussions are diagnosed," said Brian McGlynn, founder and chief technical officer of BioDirection. "Our technology platform is capable of quantitatively measuring protein biomarkers associated with brain injury at ng/mL concentrations and has the potential to aid in a broad spectrum of applications in TBI management."
BioDirection, Inc. is a privately held medical device company developing novel and rapid point-of-care technologies for the objective diagnosis and management of concussion and other traumatic brain injury (TBI). The company's lead product, the Tbit™ blood test, delivers rapid biologically-based results to accurately confirm a traumatic brain injury/concussion. BioDirection's platform system utilizes a patented bio-nanowire technology with the potential for use in a range of applications in point-of-care diagnostics. To learn more about BioDirection visit http://www.biodirection.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biodirection-inc-holds-pre-submission-meeting-with-fda-300369551.html
SOURCE BioDirection, Inc.